Mangoceuticals, Common Net Worth
Mangoceuticals, Common Net Worth Breakdown | MGRX |
Mangoceuticals, Common Net Worth Analysis
Mangoceuticals, Common's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mangoceuticals, Common's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mangoceuticals, Common's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mangoceuticals, Common's net worth analysis. One common approach is to calculate Mangoceuticals, Common's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mangoceuticals, Common's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mangoceuticals, Common's net worth. This approach calculates the present value of Mangoceuticals, Common's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mangoceuticals, Common's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mangoceuticals, Common's net worth. This involves comparing Mangoceuticals, Common's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mangoceuticals, Common's net worth relative to its peers.
To determine if Mangoceuticals, Common is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mangoceuticals, Common's net worth research are outlined below:
| Mangoceuticals, Common generated a negative expected return over the last 90 days | |
| Mangoceuticals, Common has high historical volatility and very poor performance | |
| Mangoceuticals, Common has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 731.49 K. Net Loss for the year was (9.21 M) with profit before overhead, payroll, taxes, and interest of 4.85 K. | |
| Mangoceuticals, Common generates negative cash flow from operations | |
| About 37.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Eugene Johnston of 25000 shares of Mangoceuticals, Common subject to Rule 16b-3 |
Mangoceuticals, Common uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mangoceuticals, Common Stock. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mangoceuticals, Common's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of January 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Follow Mangoceuticals, Common's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.29 M.Market Cap |
|
Project Mangoceuticals, Common's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (8.77) | (8.33) | |
| Return On Capital Employed | (10.98) | (10.43) | |
| Return On Assets | (8.77) | (8.33) | |
| Return On Equity | (11.89) | (11.30) |
When accessing Mangoceuticals, Common's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mangoceuticals, Common's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mangoceuticals, Common's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Mangoceuticals, Common's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mangoceuticals, Common Stock. Check Mangoceuticals, Common's Beneish M Score to see the likelihood of Mangoceuticals, Common's management manipulating its earnings.
Evaluate Mangoceuticals, Common's management efficiency
Mangoceuticals, Common has return on total asset (ROA) of (0.5751) % which means that it has lost $0.5751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0844) %, meaning that it created substantial loss on money invested by shareholders. Mangoceuticals, Common's management efficiency ratios could be used to measure how well Mangoceuticals, Common manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -8.33 in 2024. Return On Capital Employed is likely to rise to -10.43 in 2024. At this time, Mangoceuticals, Common's Net Tangible Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to rise to 3.57 in 2024, whereas Total Assets are likely to drop slightly above 761.4 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.54 | 0.57 | |
| Tangible Book Value Per Share | 0.54 | 0.57 | |
| Enterprise Value Over EBITDA | (0.58) | (0.55) | |
| Price Book Value Ratio | 7.65 | 8.03 | |
| Enterprise Value Multiple | (0.58) | (0.55) | |
| Price Fair Value | 7.65 | 8.03 | |
| Enterprise Value | 4.8 M | 4.3 M |
The strategic initiatives led by Mangoceuticals, Common's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 8.5908 | Revenue 866.8 K | Quarterly Revenue Growth 0.155 | Revenue Per Share 0.615 | Return On Equity (1.08) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mangoceuticals, Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mangoceuticals, Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mangoceuticals, Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mangoceuticals, Common Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 30th of August 2024 Other Reports | ViewVerify | |
F4 | 27th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Mangoceuticals, Common Earnings per Share Projection vs Actual
Additional Tools for Mangoceuticals, Stock Analysis
When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.